2004
DOI: 10.1002/jps.20025
|View full text |Cite
|
Sign up to set email alerts
|

Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane‐based metered dose inhalers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
18
0

Year Published

2004
2004
2022
2022

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 31 publications
(21 citation statements)
references
References 21 publications
3
18
0
Order By: Relevance
“…Another important feature of Figures 4a and b is the prediction of smaller droplet size for HFA134a propellant system compared with HFA227 propellant system, by both atomization model variants. This trend was previously observed in several studies such as Brambilla et al (1999), Stein and Myrdal (2004), and Myrdal et al (2004), who measured the residual droplet size issued from a pMDI. The trend is attributable to higher saturated vapor pressure of HFA134a compared with HFA227, providing greater energy source for flow acceleration.…”
Section: Resultssupporting
confidence: 80%
“…Another important feature of Figures 4a and b is the prediction of smaller droplet size for HFA134a propellant system compared with HFA227 propellant system, by both atomization model variants. This trend was previously observed in several studies such as Brambilla et al (1999), Stein and Myrdal (2004), and Myrdal et al (2004), who measured the residual droplet size issued from a pMDI. The trend is attributable to higher saturated vapor pressure of HFA134a compared with HFA227, providing greater energy source for flow acceleration.…”
Section: Resultssupporting
confidence: 80%
“…This is about the minimum amount required (5 mg) to improve the pulmonary function of lung transplant patients with chronic rejection (Corcoran et al, 2004). This amount could be achieved with two capsules or a higher loading in a single capsule, compared with a metered dose inhaler formulation requiring five actuations to achieve approximately half the minimum amount required (Myrdal et al, 2004).…”
Section: Aerosol Performancementioning
confidence: 98%
“…Cyclosporine A (CsA) is an immunosuppressive agent used for the prevention of lung transplant rejections (Iacono et al, 2006), autoimmune disorders (Galeazzia, Bellisaia, Manganellia, Morozzia, & Sebastianib, 2006), and for the treatment of asthma (Underwood et al, 2001). CsA is soluble in hydrofluoroalkane propellants and used in pressured metered dose inhalers (pMDI) (Myrdal, Karlage, Stein, Brown, & Haynes, 2004). It has been shown by others that non-aqueous solutions of CsA could be spray dried to produce a liquid crystal form of CsA with mass median diameters of approximately 1.2 m, depending on the organic solvent and temperature used (Lechuga-Ballesteros et al, 2000).…”
Section: Introductionmentioning
confidence: 99%
“…The instillation of liquids into pulmonary airways occurs in certain medical treatments such as surfactant replacement therapy (SRT) (Long et al 1991;Yapicioglu et al 2003;Salvia-Roiges et al 2004;Donn & Dalton 2009;Jeng, Soong & Lee 2009), partial liquid ventilation (Hirschl et al 2002;Cox et al 2003;Mikawa et al 2004;Guo et al 2009;Rasche et al 2010) and drug delivery (Jensen, Halpern & Grotberg 1994;Yu & Chien 1997;Zhang, Matar & Craster 2003;Iqbal et al 2004;Myrdal et al 2004). The effectiveness of these treatments depends on the ability to deliver the liquid into targeted areas.…”
Section: Introductionmentioning
confidence: 98%